Circumsporozoite protein (CS) is the antigenic target for RTS,S, the most advanced malaria vaccine to date. Heterologous prime-boost with the viral vectors simian adenovirus 63 (ChAd63)-modified vaccinia virus Ankara (MVA) is the most potent inducer of T-cells in humans, demonstrating significant efficacy when expressing the preerythrocytic antigen insert multiple epitope-thrombospondin-related adhesion protein (ME-TRAP). We hypothesized that ChAd63-MVA containing CS may result in a significant clinical protective efficacy.
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals / Hodgson, Susanne H; Ewer, Katie J.; Bliss, Carly M.; Edwards, Nick J.; Rampling, Thomas; Anagnostou, Nicholas A.; De Barra, Eoghan; Havelock, Tom; Bowyer, Georgina; Poulton, Ian D.; De Cassan, Simone; Longley, Rhea; Illingworth, Joseph J.; Douglas, Alexander D.; Mange, Pooja B.; Collins, Katharine A.; Roberts, Rachel; Gerry, Stephen; Berrie, Eleanor; Moyle, Sarah; Colloca, Stefano; Cortese, Riccardo; Sinden, Robert E.; Gilbert, Sarah C.; Bejon, Philip; Lawrie, Alison M.; Nicosia, Alfredo; Faust, Saul N.; Hill, Adrian V. S.. - In: THE JOURNAL OF INFECTIOUS DISEASES. - ISSN 0022-1899. - 211:7(2015), pp. 1076-1086. [10.1093/infdis/jiu579]
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals
NICOSIA, Alfredo;
2015
Abstract
Circumsporozoite protein (CS) is the antigenic target for RTS,S, the most advanced malaria vaccine to date. Heterologous prime-boost with the viral vectors simian adenovirus 63 (ChAd63)-modified vaccinia virus Ankara (MVA) is the most potent inducer of T-cells in humans, demonstrating significant efficacy when expressing the preerythrocytic antigen insert multiple epitope-thrombospondin-related adhesion protein (ME-TRAP). We hypothesized that ChAd63-MVA containing CS may result in a significant clinical protective efficacy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
